NALBUPHINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	NALBUPHINE HYDROCHLORIDE	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	070914	ANDA	Henry Schein, Inc.	0404-9918-01	1 AMPULE in 1 BAG (0404-9918-01) / 1 mL in 1 AMPULE	2022-01-13
Hospira	NALBUPHINE HYDROCHLORIDE	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	070914	ANDA	Hospira, Inc.	0409-1463-49	10 AMPULE in 1 TRAY (0409-1463-49) / 1 mL in 1 AMPULE (0409-1463-69)	2008-06-27
Hospira	NALBUPHINE HYDROCHLORIDE	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	070914	ANDA	Hospira, Inc.	0409-1463-01	10 AMPULE in 1 TRAY (0409-1463-01) / 1 mL in 1 AMPULE (0409-1463-71)	2008-06-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Nalbuphene hydrochloride, an opioid agonist-antagonist analgesic, is manufactured by a limited number of pharmaceutical companies and contract manufacturing organizations (CMOs). The market is characterized by established players and potential patent challenges impacting future supply dynamics.

What is the current status of Nalbuphene Hydrochloride production?

Nalbuphene hydrochloride is primarily manufactured by two main entities: Hikma Pharmaceuticals and Fresenius Kabi. Both companies are vertically integrated or have strong supply chain control for the active pharmaceutical ingredient (API) and the finished dosage form.

Hikma Pharmaceuticals: Holds U.S. Food and Drug Administration (FDA) approval for nalbuphine hydrochloride injection. Their manufacturing capabilities encompass API synthesis and finished product formulation.
Fresenius Kabi: Also possesses FDA approval for nalbuphine hydrochloride injection and has been a significant supplier in the market. Similar to Hikma, they maintain control over key manufacturing steps.

Beyond these two primary manufacturers, other CMOs may be involved in specific stages of the supply chain, such as intermediate synthesis or final packaging, but the direct API and finished product manufacturing is concentrated.

What are the key patents affecting Nalbuphene Hydrochloride?

The patent landscape for nalbuphine hydrochloride centers on its synthesis, purification, and specific formulations. While the compound itself has been known for decades, process patents and formulation patents continue to be relevant for market exclusivity and potential challenges.

Key Patent Areas:

Synthesis Processes: Patents often claim novel or improved methods for synthesizing the nalbuphine molecule. These can include specific reaction conditions, catalysts, or purification techniques that lead to higher yields, reduced impurities, or cost efficiencies.
Polymorphs and Crystal Forms: Different crystalline forms (polymorphs) of an API can have distinct physical properties such as solubility, stability, and bioavailability. Patents may cover specific, advantageous polymorphs of nalbuphine hydrochloride.
Formulations: Patents can protect specific drug delivery systems, such as extended-release formulations, or the combination of nalbuphine hydrochloride with other active ingredients. This is particularly relevant for developing new therapeutic applications or improving patient convenience.
Salt Forms: While nalbuphine hydrochloride is the established salt form, patents could theoretically explore other salt forms with advantageous properties, though this is less common for older established drugs.

Notable Patent Activity and Expirations:

The original patents covering nalbuphine itself have long since expired. However, subsequent patents related to manufacturing processes and specific formulations are critical.

Process Improvement Patents: Companies like Hikma and Fresenius Kabi may hold patents on their proprietary manufacturing routes. For example, a patent might claim a method for producing nalbuphine hydrochloride with a specific purity profile or a reduced environmental impact.
Formulation Patents: While nalbuphine hydrochloride is predominantly available as an injectable, there is always potential for innovation in delivery methods. Any new patents on novel formulations would extend market exclusivity for those specific products.

To illustrate, consider the following hypothetical patent scenarios:

Patent X (Hypothetical): Granted in 2015, claims a novel purification method for nalbuphine hydrochloride that achieves greater than 99.5% purity, significantly reducing residual impurities. This patent would likely expire around 2035.
Patent Y (Hypothetical): Granted in 2018, claims a stable liquid formulation of nalbuphine hydrochloride suitable for long-term storage at room temperature, overcoming stability challenges of previous formulations. This patent would likely expire around 2038.

The expiration of key process patents can open the door for generic manufacturers to enter the market, provided they can develop their own non-infringing manufacturing processes or have sufficient stockpiles of generic API.

Who are the primary manufacturers and suppliers of Nalbuphene Hydrochloride API?

The manufacturing of nalbuphine hydrochloride API is concentrated among a few key players, often linked to the finished dosage form manufacturers.

Primary API Suppliers:

Hikma Pharmaceuticals: Produces its own nalbuphine hydrochloride API for its finished products.
Fresenius Kabi: Similarly, manufactures its nalbuphine hydrochloride API internally.

Potential Third-Party API Suppliers:

While Hikma and Fresenius Kabi are the primary sources for their own products, the availability of nalbuphine hydrochloride API on the open market for other manufacturers can be limited. Companies with specialized expertise in opioid synthesis and cGMP (current Good Manufacturing Practice) compliance are required.

API manufacturers specializing in opioids: These may include companies in India or China with established expertise and regulatory compliance for opioid APIs. However, specific suppliers for nalbuphine hydrochloride API beyond the vertically integrated manufacturers are not widely publicized. This often requires direct inquiry and due diligence with API sourcing specialists.

Key Considerations for API Sourcing:

Regulatory Compliance: API must meet stringent cGMP standards and be produced in FDA-inspected facilities.
Quality Control: Robust quality control systems are essential to ensure consistent purity, potency, and absence of harmful impurities.
Supply Chain Security: Given the controlled substance nature of opioids, supply chain security and regulatory adherence are paramount.
Cost: While quality and compliance are primary, cost remains a significant factor in API procurement.

What is the regulatory landscape for Nalbuphene Hydrochloride?

Nalbuphene hydrochloride is regulated as a controlled substance in many jurisdictions due to its opioid properties. This classification imposes significant regulatory burdens on manufacturers, distributors, and prescribers.

United States Regulatory Framework:

Drug Enforcement Administration (DEA): Nalbuphene hydrochloride is scheduled under the DEA's controlled substances act. Its scheduling dictates:
- Registration Requirements: Manufacturers, distributors, and researchers must register with the DEA.
- Quotas: The DEA sets annual production quotas for Schedule II-V substances to prevent diversion.
- Record Keeping: Strict record-keeping requirements for all transactions.
- Security: Mandated security measures for storage and handling.
Food and Drug Administration (FDA): The FDA oversees drug approval, manufacturing, labeling, and post-market surveillance.
- New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs): Companies seeking to market nalbuphine hydrochloride products must obtain FDA approval through these pathways.
- cGMP Compliance: Manufacturing facilities must adhere to cGMP regulations.
- Labeling Requirements: Specific requirements for product labeling, including warnings and controlled substance status.

International Regulatory Considerations:

International Narcotics Control Board (INCB): For international trade, nalbuphine hydrochloride falls under the purview of INCB conventions, requiring import and export authorizations.
National Regulatory Authorities: Each country has its own regulatory bodies (e.g., EMA in Europe, Health Canada) with specific requirements for drug approval and controlled substance management.

Impact of Regulatory Classification:

The controlled substance classification significantly limits the number of companies that can legally manufacture and distribute nalbuphine hydrochloride. It increases compliance costs and complexities, acting as a barrier to entry for new manufacturers.

What are the future market trends and patent considerations for Nalbuphene Hydrochloride?

The future market for nalbuphine hydrochloride will be influenced by patent expirations, the development of new generic entrants, and potential shifts in therapeutic use or formulation.

Key Market Trends:

Generic Competition: As key patents expire, the market is likely to see increased competition from generic manufacturers, potentially leading to price erosion. The ability of generic companies to secure reliable API sources and navigate DEA regulations will be critical.
Supply Chain Resilience: Recent global events have highlighted the importance of resilient supply chains. Companies may seek to diversify API sources or increase domestic manufacturing capabilities.
Therapeutic Expansion: While nalbuphine hydrochloride is established, research into new therapeutic areas or combinations could emerge, potentially leading to new patent filings for novel uses.
Biosimil Considerations (Not Applicable to Small Molecules): For small molecule drugs like nalbuphine hydrochloride, the concept of biosimil is not applicable. This contrasts with biologic drugs.

Future Patent Landscape:

"Evergreening" Strategies: Pharmaceutical companies may pursue strategies to extend patent protection, such as:
- New Formulations: Developing novel delivery systems (e.g., transdermal patches, long-acting injectables) or combination products.
- New Indications: Obtaining patents for the use of nalbuphine hydrochloride in previously unapproved therapeutic areas.
- Process Patents: Continuing to file patents on improved manufacturing processes that offer cost savings or environmental benefits.
Litigation: Patent disputes between branded and generic manufacturers are common and can significantly impact market entry timelines.
Data Exclusivity: Even after patent expiry, data exclusivity periods granted by regulatory authorities can provide a limited period of market protection for new drug approvals, even for generics.

Strategic Implications for Stakeholders:

For Generic Manufacturers: Focus on developing non-infringing synthesis routes and securing robust API supply chains. Proactive engagement with regulatory bodies is essential.
For Branded Manufacturers: Explore opportunities for lifecycle management through formulation innovation and new indications to maintain market share post-patent expiry.
For Investors: Assess the strength of existing patents, the pipeline of potential generic challengers, and the regulatory hurdles for market entry.

Key Takeaways

Nalbuphene hydrochloride production is concentrated among Hikma Pharmaceuticals and Fresenius Kabi, who largely control their API and finished product manufacturing.
The patent landscape for nalbuphine hydrochloride is characterized by expired composition-of-matter patents, with ongoing relevance for process and formulation patents.
Regulatory oversight by the DEA and FDA, particularly the controlled substance classification, presents significant barriers to entry and dictates stringent manufacturing and distribution protocols.
Future market dynamics will be shaped by the emergence of generic competition, the ability of manufacturers to navigate patent cliffs, and the ongoing need for supply chain security and regulatory compliance.

Frequently Asked Questions

1. Are there any currently approved generic versions of nalbuphine hydrochloride injection in the United States?

As of the latest available information, the market for nalbuphine hydrochloride injection in the United States is primarily served by Hikma Pharmaceuticals and Fresenius Kabi. The availability of a broad range of generic competitors can be influenced by patent status and the complexities of manufacturing controlled substances. Specific generic approvals can be verified through the FDA's Orange Book database.

2. What are the primary challenges for a new company looking to enter the nalbuphine hydrochloride API market?

The main challenges include navigating the stringent DEA regulations for controlled substances, establishing a cGMP-compliant manufacturing facility, developing a cost-effective and non-infringing synthesis process, and securing the necessary regulatory approvals from agencies like the FDA. The specialized nature of opioid synthesis also requires significant technical expertise and capital investment.

3. How does the controlled substance classification impact the global supply of nalbuphine hydrochloride?

The classification as a controlled substance in many countries means that international trade in nalbuphine hydrochloride is subject to strict quotas, import/export permits, and monitoring by international bodies like the INCB. This limits the number of authorized manufacturers and distributors and adds significant complexity to cross-border transactions, potentially impacting global availability and pricing.

4. Can new patents be filed for nalbuphine hydrochloride if the original patent has expired?

Yes, while the original patent covering the nalbuphine molecule itself has expired, new patents can be filed for novel and non-obvious inventions related to nalbuphine hydrochloride. These typically include new or improved manufacturing processes, specific crystalline forms (polymorphs), novel formulations (e.g., extended-release, alternative delivery systems), or new therapeutic uses. These subsequent patents can extend market exclusivity for specific products or methods.

5. What are the implications of supply chain disruptions for nalbuphine hydrochloride?

Given the concentrated manufacturing base and the controlled substance status, supply chain disruptions for nalbuphine hydrochloride can have significant consequences. These can include shortages, price volatility, and potential impacts on patient access to pain management therapies. Diversification of manufacturing sites and robust inventory management are key strategies to mitigate these risks.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (Note: Specific product and approval dates for nalbuphine hydrochloride can be queried through this database). [2] Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/controlled-substances-act [3] International Narcotics Control Board. (n.d.). Global Overview of Drug Prevention and Control. Retrieved from https://www.incb.org/ [4] Hikma Pharmaceuticals. (n.d.). Product Information. (Note: Specific product details are often proprietary or found in investor relations materials and regulatory filings. General product offerings can be inferred from market presence). [5] Fresenius Kabi. (n.d.). Product Information. (Note: Similar to Hikma, specific product details are often proprietary or found in investor relations materials and regulatory filings).

Suppliers and packagers for generic pharmaceutical drug: NALBUPHINE HYDROCHLORIDE